These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 2711649)

  • 1. [The effect of mercasolyl on immunologic indicators in patients with diffuse toxic goiter].
    Epishin AV; Solomko LD; Epishina NA; Kuz'mich IuP
    Vrach Delo; 1989 Feb; (2):11-4. PubMed ID: 2711649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunologic reactions in patients with diffuse toxic goiter after mercasolyl treatment].
    Epishin AV
    Klin Med (Mosk); 1984 Aug; 62(8):90-3. PubMed ID: 6333549
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experience using lithium carbonate in the complex treatment of diffuse toxic goiter].
    Petrov NM
    Ter Arkh; 1985; 57(12):32-6. PubMed ID: 3937256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dynamics of thyrostimulating immunoglobulin levels during treatment of diffuse toxic goiter].
    Sviridenko NIu; Mkrtukova NA; Kraĭnova SI; Nefedov SB; Kandror VI
    Probl Endokrinol (Mosk); 1991; 37(1):15-7. PubMed ID: 1674150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibodies to the plasma membranes of thyrocytes in patients with diffuse toxic goiter during treatment with mercazole].
    Saarma VA; Podar TU
    Probl Endokrinol (Mosk); 1988; 34(5):17-9. PubMed ID: 3217382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative curative effect of Mercasolyl and potassium perchlorate in treating patients with diffuse toxic goiter].
    Anvarova ShS
    Sov Med; 1972 Jul; 35(7):84-8. PubMed ID: 4115205
    [No Abstract]   [Full Text] [Related]  

  • 7. [Remote results of the surgical treatment of patients with diffuse toxic goiter depending on the immunologic status].
    Deĭkalo IN; Gerasimenko AA; Epishin AV
    Vestn Khir Im I I Grek; 1985 Feb; 134(2):11-5. PubMed ID: 3873741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of merkazolyl on the level of thyrostimulating immunoglobulins of the blood in patients with diffuse toxic goiter].
    Oleĭnik VA; Khalangot ND
    Probl Endokrinol (Mosk); 1989; 35(1):32-5. PubMed ID: 2717572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The determination of natural killer cells in the peripheral blood of patients with diffuse toxic goiter].
    Podil'chak MD; Terletskaia LM; Kun ND
    Vrach Delo; 1990 May; (5):51-2. PubMed ID: 2396392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Status of natural immunity and the ways of its enhancement in patients with goiter].
    Kirillov IuB; Korviakov AP; Potapov AP; Morozov SV
    Khirurgiia (Mosk); 1990 Dec; (12):72-5. PubMed ID: 2079823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical relevance of the determination of TSH-binding inhibitory immunoglobulins (TBII) in patients with immunogenic hyperthyroidism in methimazole therapy].
    Heberling HJ; Bierwolf B; Kuhlmann E; Klugmann T; Dietel P; Fischer S
    Dtsch Z Verdau Stoffwechselkr; 1987; 47(6):331-6. PubMed ID: 2896115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No prognostic value of thyroid autoantibodies changes during and after methimazole therapy in patients with Graves' disease.
    Lattanzi V; Ciampolillo A; Vincenti C; Giorgino R
    Boll Soc Ital Biol Sper; 1985 Apr; 61(4):507-13. PubMed ID: 3840026
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of thyrostatic therapy on various immunologic indices in patients with diffuse toxic goiter].
    Vnotchenko SL; Starkova NT; Mkrtumova NA
    Probl Endokrinol (Mosk); 1983; 29(4):19-23. PubMed ID: 6604271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases.
    Bossowski A; Czarnocka B; Bardadin K; Urban M; Niedziela M; Dadan J
    Horm Res; 2008; 70(3):155-64. PubMed ID: 18663316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
    Nielsen CH; El Fassi D; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid antibodies in endemic goiter in lower Silesia studied in a sample of the population in 1969.
    Podleski WK; Zawada W
    Arch Immunol Ther Exp (Warsz); 1970; 18(6):664-78. PubMed ID: 5493085
    [No Abstract]   [Full Text] [Related]  

  • 19. [Characteristics of the clinical picture, hormonal status and humoral immunity in older patients with diffuse toxic goiter].
    Natarov VV; Grinchenko TS; Afanas'eva NI; Pesotskaia PM; Nikolaeva VM
    Ter Arkh; 1988; 60(12):96-8. PubMed ID: 3247664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of glucocorticosteroids on the immunological indices of diffuse toxic goiter patients].
    Epishin AV
    Vrach Delo; 1984 Jul; (7):41-3. PubMed ID: 6332424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.